|
Hutchmed China Ltd on Monday said it has begun a Phase II/III trial of sovleplenib in adult patients with warm antibody autoimmune haemolytic anaemia in China.
wAIHA is an autoimmune disorder that can lead to anemia and has limited treatment options.
The first patient received the first dose on September 30 as part of the randomised, double blind, placebo-controlled clinical trial. Around 110 patients are expects to enrol on the trial, the Hong Kong-based biopharmaceutical company added.
Hutchmed said that the Phase II stage of the study is to evaluate the safety and preliminary efficacy of sovleplenib in adult patients with wAIHA.
‘Sovleplenib is a novel, investigational, selective small molecule inhibitor for oral administration targeting the spleen tyrosine kinase, also known as Syk. Syk is a major component in B-cell receptor and Fc receptor signaling and is an established target for the treatment of multiple subtypes of B-cell lymphomas and autoimmune disorders,’ the company explained.
An fc receptor is a protein on the surface on some cells.
If the first stage is positive, the Phase III stage will be initiated to confirm the efficacy and safety of Sovleplenib.
Shares in Hutchmed were down 0.1% to 151.67 pence each in London on Monday morning.
Copyright 2022 Alliance News Limited. All Rights Reserved.
|
